Header Logo

Connection

JORGE E CORTES to Clinical Trials as Topic

Back to Details
This is a "connection" page, showing publications JORGE E CORTES has written about Clinical Trials as Topic.
JORGE E CORTES
Connection Strength
1.903
Clinical Trials as Topic
  1. Determination of fitness and therapeutic options in older patients with acute myeloid leukemia. Am J Hematol. 2021 04 01; 96(4):493-507.
    View in: PubMed
    Score: 0.089
  2. Hedgehog signaling inhibitors in solid and hematological cancers. Cancer Treat Rev. 2019 Jun; 76:41-50.
    View in: PubMed
    Score: 0.079
  3. A second-generation TKI should always be used as initial therapy for CML. Blood Adv. 2018 12 26; 2(24):3653-3655.
    View in: PubMed
    Score: 0.077
  4. Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. Clin Lymphoma Myeloma Leuk. 2017 10; 17(10):684-695.e6.
    View in: PubMed
    Score: 0.070
  5. Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Curr Treat Options Oncol. 2017 03; 18(3):17.
    View in: PubMed
    Score: 0.068
  6. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 02 15; 123(4):609-616.
    View in: PubMed
    Score: 0.067
  7. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93.
    View in: PubMed
    Score: 0.060
  8. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015 Jan; 16(1):95-106.
    View in: PubMed
    Score: 0.058
  9. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol. 2013 Jun; 14(2):127-43.
    View in: PubMed
    Score: 0.053
  10. A journey searching for a cure for leukemia. Interviewed by Natasha Galukande. Future Oncol. 2013 Jun; 9(6):785-7.
    View in: PubMed
    Score: 0.053
  11. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. J Natl Compr Canc Netw. 2012 Oct 01; 10 Suppl 3:S1-S13.
    View in: PubMed
    Score: 0.050
  12. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era? Cancer. 2011 Aug 01; 117(15):3293-304.
    View in: PubMed
    Score: 0.045
  13. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1674-83.
    View in: PubMed
    Score: 0.045
  14. Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2010 Dec; 10(6):443-51.
    View in: PubMed
    Score: 0.044
  15. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep. 2010 Sep; 12(5):302-13.
    View in: PubMed
    Score: 0.044
  16. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009 Aug 15; 115(16):3709-18.
    View in: PubMed
    Score: 0.040
  17. Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S272-9.
    View in: PubMed
    Score: 0.039
  18. Standard management of patients with chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S382-90.
    View in: PubMed
    Score: 0.039
  19. The next generation of therapies for chronic myeloid leukemia. Clin Lymphoma Myeloma. 2009; 9 Suppl 4:S395-403.
    View in: PubMed
    Score: 0.039
  20. Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future Oncol. 2008 Oct; 4(5):611-21.
    View in: PubMed
    Score: 0.038
  21. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008 Jul 15; 14(14):4392-9.
    View in: PubMed
    Score: 0.038
  22. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. IDrugs. 2008 May; 11(5):356-72.
    View in: PubMed
    Score: 0.037
  23. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother. 2008 Apr; 9(6):1029-37.
    View in: PubMed
    Score: 0.037
  24. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S75-81.
    View in: PubMed
    Score: 0.037
  25. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma. 2008 Mar; 8 Suppl 3:S82-8.
    View in: PubMed
    Score: 0.037
  26. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007 Oct 15; 110(8):2991-5.
    View in: PubMed
    Score: 0.035
  27. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 3:S105-12.
    View in: PubMed
    Score: 0.034
  28. New strategies in chronic myeloid leukemia. Int J Hematol. 2006 May; 83(4):289-93.
    View in: PubMed
    Score: 0.032
  29. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005 Sep 10; 23(26):6316-24.
    View in: PubMed
    Score: 0.031
  30. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma. 2004 Nov; 45(11):2187-95.
    View in: PubMed
    Score: 0.029
  31. Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol. 2004 Jun; 79(5):411-9.
    View in: PubMed
    Score: 0.028
  32. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer. 2004 May 15; 100(10):2064-78.
    View in: PubMed
    Score: 0.028
  33. Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Clin Lymphoma. 2003 Aug; 4 Suppl 1:S30-5.
    View in: PubMed
    Score: 0.027
  34. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. Semin Hematol. 2002 Jul; 39(3 Suppl 2):26-30.
    View in: PubMed
    Score: 0.025
  35. Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001 Feb; 15(1):145-62.
    View in: PubMed
    Score: 0.022
  36. The 51st annual meeting of the American Society of Hematology. Clin Lymphoma Myeloma Leuk. 2010 Apr; 10(2):90-7.
    View in: PubMed
    Score: 0.021
  37. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
    View in: PubMed
    Score: 0.018
  38. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016 09; 48:84-91.
    View in: PubMed
    Score: 0.016
  39. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013 Oct; 50(4):271-83.
    View in: PubMed
    Score: 0.013
  40. Bosutinib for the treatment of chronic myeloid leukemia in chronic phase. Drugs Today (Barc). 2012 Mar; 48(3):177-88.
    View in: PubMed
    Score: 0.012
  41. Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2011 Sep; 6(3):187-94.
    View in: PubMed
    Score: 0.012
  42. Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2011 Jun; 4(3):253-60.
    View in: PubMed
    Score: 0.011
  43. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S101-10.
    View in: PubMed
    Score: 0.011
  44. Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia. Expert Opin Emerg Drugs. 2011 Sep; 16(3):407-23.
    View in: PubMed
    Score: 0.011
  45. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs. 2010 Dec; 11(12):1450-65.
    View in: PubMed
    Score: 0.011
  46. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 2011 Feb 15; 117(4):688-97.
    View in: PubMed
    Score: 0.011
  47. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009 Dec 01; 115(23):5382-93.
    View in: PubMed
    Score: 0.010
  48. Imatinib and beyond--exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol. 2009 Sep; 6(9):535-43.
    View in: PubMed
    Score: 0.010
  49. First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol. 2009 May; 84(5):287-93.
    View in: PubMed
    Score: 0.010
  50. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009 Jun 18; 113(25):6315-21.
    View in: PubMed
    Score: 0.010
  51. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer. 2009 Apr 01; 115(7):1381-94.
    View in: PubMed
    Score: 0.010
  52. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009 Apr; 16(2):122-31.
    View in: PubMed
    Score: 0.010
  53. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 01; 115(3):551-60.
    View in: PubMed
    Score: 0.010
  54. Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opin Investig Drugs. 2008 Jul; 17(7):1127-36.
    View in: PubMed
    Score: 0.009
  55. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008 Jan; 8(1):99-110.
    View in: PubMed
    Score: 0.009
  56. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007 Oct; 6(10):834-48.
    View in: PubMed
    Score: 0.009
  57. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs. 2007 Jul; 10(7):468-79.
    View in: PubMed
    Score: 0.009
  58. New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Jul; 2(3):183-9.
    View in: PubMed
    Score: 0.009
  59. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs? Oncology (Williston Park). 2007 May; 21(6):653-62; discussion 663-4, 667-8.
    View in: PubMed
    Score: 0.009
  60. Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia. Curr Hematol Malig Rep. 2007 May; 2(2):83-8.
    View in: PubMed
    Score: 0.009
  61. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma. 2007 Mar; 7 Suppl 2:S51-7.
    View in: PubMed
    Score: 0.009
  62. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007 Jan; 44(1 Suppl 1):S25-31.
    View in: PubMed
    Score: 0.008
  63. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol. 2006 Nov; 18(6):578-83.
    View in: PubMed
    Score: 0.008
  64. New agents in the treatment of acute lymphocytic leukaemia. Best Pract Res Clin Haematol. 2002 Dec; 15(4):771-90.
    View in: PubMed
    Score: 0.006
  65. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol. 2002 Oct; 39(4 Suppl 3):20-4.
    View in: PubMed
    Score: 0.006
  66. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program. 2002; 111-35.
    View in: PubMed
    Score: 0.006
  67. Antiangiogenic therapy in leukemia. Acta Haematol. 2001; 106(4):190-207.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.